Analyst Price Target is $50.77
▲ +36.91% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for NuVasive in the last 3 months. The average price target is $50.77, with a high forecast of $58.00 and a low forecast of $44.50. The average price target represents a 36.91% upside from the last price of $37.08.
Current Consensus is
The current consensus among 11 polled investment analysts is to hold stock in NuVasive. This Hold consensus rating has held steady for over two years.
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.